[go: up one dir, main page]

MA32349B1 - Antagonistes de la voie hedgehog a base de phtalazines disubstituees - Google Patents

Antagonistes de la voie hedgehog a base de phtalazines disubstituees

Info

Publication number
MA32349B1
MA32349B1 MA33284A MA33284A MA32349B1 MA 32349 B1 MA32349 B1 MA 32349B1 MA 33284 A MA33284 A MA 33284A MA 33284 A MA33284 A MA 33284A MA 32349 B1 MA32349 B1 MA 32349B1
Authority
MA
Morocco
Prior art keywords
antagonists
phtalazines
disubstituted
hedgehog pathway
pathway based
Prior art date
Application number
MA33284A
Other languages
Arabic (ar)
English (en)
Inventor
Philip Arthur Hipskind
Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA32349B1 publication Critical patent/MA32349B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux antagonistes de la voie de la protéine hedgehog de phtalazine 1,4-disubstituée utiles dans le traitement du cancer.
MA33284A 2008-04-29 2010-10-25 Antagonistes de la voie hedgehog a base de phtalazines disubstituees MA32349B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4872908P 2008-04-29 2008-04-29
PCT/US2009/039065 WO2009134574A2 (fr) 2008-04-29 2009-04-01 Antagonistes de la voie de la protéine hedgehog de phtalazine disubstituée

Publications (1)

Publication Number Publication Date
MA32349B1 true MA32349B1 (fr) 2011-06-01

Family

ID=40846962

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33284A MA32349B1 (fr) 2008-04-29 2010-10-25 Antagonistes de la voie hedgehog a base de phtalazines disubstituees

Country Status (22)

Country Link
US (1) US7981892B2 (fr)
EP (1) EP2294061A2 (fr)
JP (1) JP5442717B2 (fr)
KR (1) KR101260116B1 (fr)
CN (1) CN102066353B (fr)
AU (1) AU2009241561B2 (fr)
BR (1) BRPI0911618A2 (fr)
CA (1) CA2723042A1 (fr)
CO (1) CO6300945A2 (fr)
CR (1) CR11741A (fr)
DO (1) DOP2010000302A (fr)
EA (1) EA201071248A1 (fr)
EC (1) ECSP10010577A (fr)
HN (1) HN2010002157A (fr)
IL (1) IL208211A0 (fr)
MA (1) MA32349B1 (fr)
MX (1) MX2010011948A (fr)
MY (1) MY159491A (fr)
NZ (1) NZ588001A (fr)
UA (1) UA102250C2 (fr)
WO (1) WO2009134574A2 (fr)
ZA (1) ZA201006695B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159491A (en) 2008-04-29 2017-01-13 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
JP2012507535A (ja) * 2008-11-03 2012-03-29 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
MX2011005176A (es) * 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
CN102665700A (zh) * 2009-11-18 2012-09-12 诺瓦提斯公司 治疗实体瘤和其它恶性肿瘤的方法和组合物
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
WO2014043608A2 (fr) * 2012-09-17 2014-03-20 Duke University Modulateurs de smoothened et leurs procédés d'utilisation
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
CA3198661A1 (fr) 2020-10-13 2022-04-21 Endeavor Biomedicines, Inc. Methodes de traitement de la fibrose

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
IL124461A (en) 1996-01-15 2000-07-26 Janssen Pharmaceutica Nv Angiogenesis inhibiting 3-(1,2,4-thiadiazol-5-yl)piperazine pyridazine derivatives their preparation and pharmaceutical compositions containing them
IL138645A0 (en) 1998-04-09 2001-10-31 Univ Johns Hopkins Med Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
EP1183040B1 (fr) 1999-06-08 2004-12-01 Lorantis Limited Utilisation therapeutique d'un inhibiteur du signal hedgehog
DE60322869D1 (de) 2002-04-22 2008-09-25 Univ Johns Hopkins Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
WO2004020599A2 (fr) 2002-08-29 2004-03-11 Curis, Inc. Antagonistes de la voie hedgehog, methodes et applications correspondantes
US8067608B2 (en) * 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
JP5221952B2 (ja) 2004-05-08 2013-06-26 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド ３−アリール−５，６−ジ置換ピリダジン類
KR101366414B1 (ko) * 2004-09-02 2014-03-18 쿠리스 인코퍼레이션 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (fr) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides comme modulateurs du récepteur EP2
DK2137162T3 (en) 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
AU2008269128B2 (en) * 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
MY159491A (en) 2008-04-29 2017-01-13 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
JP2012507535A (ja) 2008-11-03 2012-03-29 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
ECSP10010577A (es) 2010-11-30
AU2009241561B2 (en) 2013-05-16
EP2294061A2 (fr) 2011-03-16
UA102250C2 (ru) 2013-06-25
CN102066353A (zh) 2011-05-18
WO2009134574A2 (fr) 2009-11-05
US20110046143A1 (en) 2011-02-24
JP5442717B2 (ja) 2014-03-12
DOP2010000302A (es) 2010-11-15
MX2010011948A (es) 2010-12-14
CO6300945A2 (es) 2011-07-21
IL208211A0 (en) 2010-12-30
CR11741A (es) 2011-01-05
WO2009134574A3 (fr) 2014-09-04
MY159491A (en) 2017-01-13
AU2009241561A1 (en) 2009-11-05
JP2011527666A (ja) 2011-11-04
CN102066353B (zh) 2013-12-11
KR20100126580A (ko) 2010-12-01
EA201071248A1 (ru) 2011-06-30
CA2723042A1 (fr) 2009-11-05
BRPI0911618A2 (pt) 2019-09-24
HN2010002157A (es) 2014-09-08
NZ588001A (en) 2012-06-29
ZA201006695B (en) 2012-09-26
US7981892B2 (en) 2011-07-19
KR101260116B1 (ko) 2013-05-02

Similar Documents

Publication Publication Date Title
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201170227A1 (ru) Имидазолкарбоксамиды
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
MX346924B (es) Compuestos de diarilhidantoina.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA200700717A1 (ru) Сульфонамиды
SV2011003857A (es) Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
CY1110891T1 (el) Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
CY1111328T1 (el) Χαρακτηρισμος: αξομαδολη για τη θεραπεια πονου σε αρθριτιδα
ATE512185T1 (de) Heterobifunktionelle polyethylenglycol-reagenzien
ATE499138T1 (de) Implantierbare vorrichtung
TN2010000489A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου
CL2008000270S1 (es) Perfil.
CL2008000258S1 (es) Perfil.
CL2008000262S1 (es) Perfil.
CL2008000267S1 (es) Perfil.
CL2008000256S1 (es) Perfil.